4.6 Article

The BRAFV600E Mutation Is Not a Risk Factor for More Aggressive Tumor Behavior in Radiogenic and Sporadic Papillary Thyroid Carcinoma at a Young Age

期刊

CANCERS
卷 13, 期 23, 页码 -

出版社

MDPI
DOI: 10.3390/cancers13236038

关键词

papillary thyroid carcinoma; BRAF(V600E); Chernobyl; immunohistochemistry; VE1 antibody; Ki67 labeling index

类别

资金

  1. Atomic Bomb Disease Institute
  2. Nagasaki University
  3. Japan Society for the Promotion of Science (JSPS) [19K07471, 19KK02670001]
  4. [U24CA082102]
  5. Grants-in-Aid for Scientific Research [19K07471] Funding Source: KAKEN

向作者/读者索取更多资源

The frequency of BRAF(V600E) in young Ukrainian patients with radiogenic and sporadic papillary thyroid carcinomas increases with age, but does not confer a more aggressive course regardless of tumor etiology. Major clinicopathological differences between radiogenic and sporadic PTCs are observed among the BRAF(V600E)-negative tumors.
Simple Summary Analysis of the groups of young Ukrainian patients (aged <= 28 years) with radiogenic and sporadic papillary thyroid carcinomas (PTCs) showed that the frequency of BRAF(V600E) was increasing with patient age, consistently remaining lower in radiogenic PTCs. In both etiopathogenic groups, the BRAF(V600E)-positive PTCs more frequently had a dominant papillary growth pattern, smaller tumor size, higher Ki67 labeling index, and a frequency of the major indicators of tumor invasiveness that is lower than or equal to that of the BRAF(V600E)-negative tumors. Comparison of the BRAF(V600E)-positive PTCs across the groups found a virtual absence of differences, while the BRAF(V600E)-negative tumors differed markedly and displayed a higher frequency of invasive tumor features in the radiogenic PTCs. Hence, there is evidence that BRAF(V600E) does not confer a more aggressive course of PTC in young patients regardless of tumor etiology. Histopathological changes in the fusion oncogene-driven papillary thyroid carcinomas (PTCs) from children and adolescents exposed to Chernobyl fallout have been extensively studied. However, characteristics of the radiogenic BRAF(V600E)-positive PTCs, whose proportion is growing with time, are not well described yet. We analyzed the relationship between the BRAF(V600E) status (determined immunohistochemically with the VE1 antibody) and the clinicopathological features of 247 radiogenic and 138 sporadic PTCs from young Ukrainian patients aged <= 28 years. The frequency of BRAF(V600E) was increasing with patient age, consistently remaining lower in radiogenic PTCs. In both etiopathogenic groups, the BRAF(V600E)-positive PTCs more frequently had a dominant papillary growth pattern, smaller tumor size, higher Ki67 labeling index, and a frequency of the major indicators of tumor invasiveness that is lower than or equal to that of the BRAF(V600E)-negative tumors. Comparison of the BRAF(V600E)-positive PTCs across the groups found a virtual absence of differences. In contrast, the BRAF(V600E)-negative radiogenic PTCs displayed less frequent dominant papillary and more frequent solid growth patterns, lower Ki67 labeling index, and higher invasiveness than the BRAF(V600E)-negative sporadic tumors. Thus, BRAF(V600E) is not associated with a more aggressive course of PTC in young patients regardless of etiology. The major clinicopathological differences between the radiogenic and sporadic PTCs are observed among the BRAF(V600E)-negative tumors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据